Clinical evidence has shown that the presence of immune cells inside the tumor might predict whether a patient will respond to checkpoint blockade therapy. However, we still do not fully understand the factors that control the infiltration of immune cells into the tumor mass, and why some patients have pre-existing immune infiltration while others lack this type of anti-tumor immune response. Using a biopsy from a human patient with non-small cell lung cancer, this image shows a wide view where Sox2 tumor cells are labeled in red and cytotoxic T cells in white, and T cells are mainly located outside the Sox2- positive tumor regions.

In our lab, we are studying how the expression of oncogenes, like Sox2, in tumor cells can make themselves “invisible” to the immune system. If we learn how differences in oncogene expression lead to differences in immune cell infiltration, we can engineer new therapies to potentiate the immune response, allowing the immune system to see the cancer cells and destroy them, thereby improving treatment outcomes.